Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27144977 | 0.81 | KDM4E (0.33) | KDM4ESRCPTGER4ALDH1A1ALDH1A3 | |
| SCHEMBL335665 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1ALDH1A3PIK3CDPOLB | |
| SCHEMBL13198899 | 0.78 | EGLN2 (0.38) | KDM4EALDH1A1JAK2JAK1PIK3CD | |
| SCHEMBL31457178 | 0.77 | NPC1 (0.37) | KDM4EALDH1A1HPGDARPOLB | |
| SCHEMBL20168396 | 0.76 | KCNJ1 (0.41) | ALDH1A1HPGDJAK2JAK1 | |
| SCHEMBL20614198 | 0.74 | CHRNB2 (0.38) | KDM4EPTGER4ALDH1A1HPGDGLA | |
| SCHEMBL335598 | 0.74 | ALDH1A1 (0.39) | KDM4ESRCPTGER4ALDH1A1ALDH1A3 | |
| SCHEMBL4918585 | 0.74 | NOS3 (0.46) | KDM4EALDH1A1JAK2JAK1CYP2A6 | |
| SCHEMBL30590409 | 0.74 | ALDH1A1 (0.39) | KDM4ESRCPTGER4ALDH1A1ALDH1A3 | |
| SCHEMBL29951110 | 0.72 | SRC (0.36) | KDM4ESRCPTGER4ALDH1A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661510-A | Isoxazoline substituted pyridine amide compound and preparation method and application thereof | 华南农业大学 | 2025-03-21 | — | — | CN | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | KDM4E 4508/4885SRC 3421/4885PTGER4 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.